Key Drivers
- EBITDA Turnaround
- Heavy Leverage
- Weak Cash Flow
AIAI Summary
QDEL is now best viewed as a turnaround story rather than a steady diagnostics compounder, with the key investment test being whether cost cuts, demand normalization, and LEX commercialization can stabilize margins and free cash flow fast enough to justify a re-rating despite weak earnings leverage, China disruption, and leverage pressure.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •EBITDA Turnaround
- •Heavy Leverage
- •Weak Cash Flow
QDEL shows solid gross margins and a recent EBITDA improvement, but persistent losses, negative cash flow, and heavy leverage keep the investment case under pressure.
క క
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •$10 support
- •Weak bounce
QDEL is technically weak in the last month, with lower highs and repeated failure at $12.30–$12.64, while $10.00 is acting as near-term support and a move back above $11.40–$12.64 is needed to improve the outlook.
Sharp rebound from $9.96 to $11.40 after testing support suggests short-term stabilization
Sentiment & News
Key News Insights:
- •LEX Expansion
- •Revenue Pressure
- •Mix Shift
QuidelOrtho is in a transitional phase, as the LEX acquisition and newer diagnostic growth areas offset weak legacy testing demand, falling revenue, and margin/cash-flow pressure.
The news is mildly negative for the instrument near term, with growth initiatives offering a longer-term offset to still-weak core testing trends
Similar Companies in Healthcare
Other companies in the same sector with AI ratings